A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia

Journal of Musculoskeletal Pain

Volumn 6, Issue 2, 1998, Pages 5-17

  Ginsberg, Francis ^a   Joos, Erika ^b   Géczy, Joseph ^c   Bruhwyler, Jacques ^c   Vandekerckhove, Kristof ^c   Famaey, Jean Pierre ^a,c  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c Therabel Pharma Belgium   (Belgium)

Author keywords

Fibromyalgia; Monoamine oxidase; Pirlindole

Indexed keywords

MONOAMINE OXIDASE A INHIBITOR; PIRLINDOLE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPOTENSION; MALE; MORNING STIFFNESS; NAUSEA; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEDATION; VERTIGO; VOMITING;

EID: 0031851676     PISSN: 10582452     EISSN: None     Source Type: Journal    
DOI: 10.1300/J094v06n02_02     Document Type: Article

References (36)

1. Bennett RM: Fibromyalgia and the facts. Sense or nonsense. Rheum Dis Clin N Am 19:45-59, 1993.
2. Boissevain MD, McGain GA: Toward an integrated understanding of fibromyalgia syndromes. I. Medical and pathophysiological aspects. Pain 45: 227-238, 1991.
3. Bradley LA, Alarcón GS: Fibromyalgia. In Koopman WJ, ed. Arthritis and allied conditions. A textbook of rheumatology. 13th edit. Baltimore, Williams & Wilkins, 1997, pp. 1619-1640.
4. Veale D, Kavanagh G, Fielding JF, Fitzgerald O: Primary fibrom̀yalgia and the irritable bowel syndrome: different expressions of a common pathogenetic process. Br Med J 30: 220-222, 1991.
5. Hench PK: Nonarticular rheumatism. Twenty-second rheumatism review: review of the American and English literature for the years 1973 and 1974. Arthritis Rheum 19(Suppl): 1081-1089, 1976.
6. Powers R: Fibromyalgia: an age-old malady begging for respect. J General Intern Med 8:93-105, 1993.
7. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell U, Sheon PP: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33:160-172, 1990.
8. Wolfe F, Ross K, Anderson J, Russell U, Hebert L: The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum 38:19-28, 1995.
9. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC: Plasma tryptophan and other amino-acids in primary fibromyalgia: a controlled study. J Rheumatol 19:90-94, 1992.
10. Russell, IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, Lopez Y, MacKillip F: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgial syndrome. Arthritis Rheum 37:1593-1601, 1994.
11. Crofford LJ, Pillemer SR, Kalogeras KT, Cash MJ, Michelson D, Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL: Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 37:1583-1592, 1994.
12. Lund N, Bengtsson A, Thorborg P: Muscle tissue oxygen pressure in primary fibromyalgia. Scand J Rheumatol 15:165-173, 1986.
13. Bengtsson A, Henriksson KG: The muscle in fibromyalgia. A review of Swedish studies. J Rheumatol 19:144-149, 1989.
14. Bengtsson A, Henriksson KG, Larsson J: Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia. Arthritis Rheum 29:817-821, 1986.
15. White KP, Harth M: An analytical review of 24 controlled clinical trials for fibromyalgia syndrome (FMS). Pain 64:211-219, 1996.
16. Ginsberg F, Mancaux A, Joos E, Van hove P, Famaey JP: A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoske Pain 4(3):37-47, 1996.
17. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, Edworthy SM, Baron M, Koehler BE, Fam AG, Bellamy N, Guimont C: Comparison of amitriptyline, cyclobenzaprine and placebo in the treatment of fibromyalgia: a randomized double-blind clinical trial. Arthritis Rheum 37:32-40, 1994.
18. Wysenbeek AJ, Mor F, Lurie Y, Weinberger A: Imipramine for the treatment of fibrositis: a therapeutic trial. Ann Rheum Dis 44:752-753, 1985.
19. Caruso I, Sarzi Puttini PC, Boccassini L, Santandrea S, Locati M, Volpato R, Montrone F, Benvenuti C, Beretta A: Double-blind study of dothiepin versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 15:154-159, 1987.
20. Wolfe F, Cathay MA, Hawley DJ: A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 23:255-259, 1994.
21. Nørregaard J, Volkmann H, Danneskiold-Samsoe B: A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 61:445-449, 1995.
22. Tyber MA: Lithium carbonate augmentation therapy in fibromyalgia. Can Med Assoc J 143:902-904, 1990.
23. Drewes AM, Andreasen A, Jennum P, Nielson KD: Zopiclone in the treatment of sleep abnormalities in fibromyalgia. Scand J Rheumatol 20:288-293, 1991.
24. Jacobsen S, Danneskiold-Samsoe B, Bach Andersen R: Oral S-adenosyl-methionine in primary fibromyalgia. Double-blind clinical evaluation. Scand J Rheumatol 20:294-302, 1991.
25. Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG: Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind placebo controlled study. Arthritis Rheum 34: 552-560, 1991.
26. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C: A randomized double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39:1852-1859, 1996.
27. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA: Platelet 3H-imipramine uptake receptor density and serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992; 19:104-109, 1992.
28. Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 35:550-556, 1992.
29. Bruhwyler J, Liégeois JF, Géczy J: Pirlindole, a selective reversible inhibitor of monoamine oxidase A. A review of its preclinical properties. Pharmacol Res (in press).
30. Bruhwyler J, Monseu MJ, Vandekerckhove K, Géczy J: Pirlindole a reversible and selective monoamine oxidase A inhibitor: A retrospective evaluation of its clinical antidepressant profile. Eur J Clin Res (in press).
31. Hewett JE, Buckelew SP, Johnson JC, Shaw SE, Huyser B, Fu YZ: Selection of measures suitable for evaluating change in fibromyalgia clinical trials. J Rheumatol 22:2307-2312, 1995.
32. Goldenberg DL: Treatment of fibromyalgia syndrome. Rheum Dis Clin N Amer 15: 61-71, 1989.
33. Buckelew SP: Fibromyalgia: A rehabilitation approach. Am J Phys Med Rehabil 68: 37-42, 1989.
34. De Wilde JE, Geerts S, Van Dorpe J, Bruhwyler J, Géczy J: A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression. Acta Psych Scand 94:404-410, 1996.
35. Tanghe A, Geerts S, Van Dorpe J, Brichard B, Bruhwyler J, Géczy J: Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. Acta Psych Scand (in press).
36. De Wilde J, Mertens C, Van Dorpe J, Bruhwyler J, Géczy J: Double-blind randomized controlled pilot study of the efficacy and tolerability of pirlindole, a reversible inhibitor of monoamine oxidase A, and mianserin, in the treatment of depression. Hum Psychopharmac 12:41-46, 1997.